Dr. Shadman presents on the use of Zanubrutinib in BTK Inhibitor-Intolerant Patients at ASH 2021

Поділитися
Вставка
  • Опубліковано 30 вер 2024
  • SCCA's Dr. Mazyar Shadman presents his abstract, Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies at the 63rd ASH Annual Meeting and Exposition. Learn more about SCCA's appearance at ASH 2021 at www.seattlecca...

КОМЕНТАРІ • 1

  • @silvialogan9226
    @silvialogan9226 2 роки тому +1

    Could Zanubrutinib put an end to all kinds of lymphomas at all four stages once and for all?